ARWR
Arrowhead Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-9/100
Last price
61.54
▲ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
62.60
Prev close
61.54
Day high
61.89
Day low
60.78
Volume
97.00K
Market cap
$8.69B
P/E (TTM)
—
52W range
34.61 – 95.49
Day trading desk
Gap from prior close
+1.72%
Prior close 61.54
VWAP
61.45
+0.14% from price
Relative volume
0.05×
Quiet session
Session range
2.99%
60.78 – 62.60
Position in range
42%
Mid range
ATR (14D)
2.52
4.09% of price
Prior day high
63.19
PDH
Prior day low
60.56
PDL
Bid / ask spread
—
Quote not published
Session volume
94.16K
Avg 1.90M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.97%
-7.7%
1M
-27.69%
-29.0%
3M
-26.74%
-30.0%
6M
-4.38%
-19.2%
YTD
-7.31%
-21.1%
1Y
+64.11%
+48.6%
3Y
+134.44%
+52.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARWR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-27.78K
Net selling
Buy transactions
1
11.88K shares
Sell transactions
5
39.66K shares
Net transactions
+6
Buys less sells
Sell : buy shares
3.3 : 1
Mixed
Insider-held shares
5.17M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | OLUKOTUN ADEOYE Y Director |
SELL | 2.00K | $173.92K | Direct |
| Aug 18, 26 | PERRY MICHAEL S Director |
SELL | 11.60K | $1.01M | Direct |
| Jun 15, 26 | COHEN MATTHEW GREGORY Director |
STOCK | 11.88K | $0 | Direct |
| May 12, 26 | LU HONGBO B Director |
SELL | 2.97K | $228.33K | Direct |
| Apr 23, 26 | HAMILTON JAMES C Officer |
SELL | 10.00K | $750.00K | Direct |
| Apr 22, 26 | APEL DANIEL JOSEPH Chief Financial Officer |
SELL | 13.10K | $934.28K | Direct |
| Mar 5, 26 | HAMILTON JAMES C Officer |
SELL | 10.00K | $641.90K | Direct |
| Jan 6, 26 | O'BRIEN PATRICK C Chief Operating Officer |
STOCK | 75.00K | $0 | Direct |
| Jan 6, 26 | O'BRIEN PATRICK C Chief Operating Officer |
STOCK | 2.50K | $0 | Direct |
| Jan 6, 26 | HAMILTON JAMES C Officer |
STOCK | 75.00K | $0 | Direct |
| Jan 6, 26 | APEL DANIEL JOSEPH Chief Financial Officer |
STOCK | 75.00K | $0 | Direct |
| Jan 5, 26 | O'BRIEN PATRICK C Chief Operating Officer |
SELL | 49.49K | $3.12M | Direct |
| Jan 5, 26 | HAMILTON JAMES C Officer |
SELL | 40.16K | $2.53M | Direct |
| Jan 2, 26 | ANZALONE CHRISTOPHER RICHARD Chief Executive Officer |
SELL | 13.19K | $871.70K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANZALONE CHRISTOPHER RICHARD |
Chief Executive Officer | 3.79M | Sale |
APEL DANIEL JOSEPH |
Chief Financial Officer | 162.91K | Sale |
FERRARI MAURO |
Director | 69.05K | Sale |
GIVEN DOUGLAS BRUCE |
Director | 124.17K | Sale |
HAMILTON JAMES C |
Officer | 226.96K | Sale |
LU HONGBO B |
Director | 52.01K | Sale |
MYSZKOWSKI KENNETH ALLEN |
Chief Financial Officer | 455.43K | Sale |
O'BRIEN PATRICK C |
Chief Operating Officer | 547.41K | Stock Award(Grant) |
PERRY MICHAEL S |
Director | 111.46K | Sale |
WADDILL WILLIAM D |
Director | 56.56K | Sale |
Fundamentals
Market cap$8.69B
Enterprise value$8.47B
Revenue (TTM)$669.49M
Gross profit$669.49M
EBITDA$-200.64M
Net income$-319.96M
EPS (TTM)$-2.28
Free cash flow$-48.63M
Total cash$1.60B
Total debt$1.38B
Book value / share$3.30
Shares outstanding141.25M
Float122.45M
Short % of float9.13%
Dividend yield0.00%
Beta (5Y)1.30
Valuation & profitability ratios
Trailing P/E—
Forward P/E-12.48
PEG ratio—
Price / sales—
Price / book18.66
EV / revenue12.66
EV / EBITDA-42.24
Gross margin100.00%
Operating margin-226.03%
Profit margin-47.79%
Return on equity-55.21%
Return on assets-8.10%
Debt / equity295.98
Current ratio5.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $829.45M | $3.55M | $240.74M | $243.23M | +23,258.2% |
| Operating revenue | $829.45M | $3.55M | $240.74M | $243.23M | +23,258.2% |
| Research & development | $607.16M | $505.87M | $353.19M | $297.31M | +20.0% |
| Selling, general & admin | $121.92M | $96.82M | $90.93M | $124.43M | +25.9% |
| Total operating expense | $731.10M | $604.63M | $445.74M | $421.74M | +20.9% |
| Operating income | $98.35M | -$601.08M | -$205.00M | -$178.51M | +116.4% |
| Net interest income | -$52.07M | -$9.63M | -$3.03M | $5.03M | -440.6% |
| Pre-tax income | $51.53M | -$612.46M | -$206.49M | -$172.71M | +108.4% |
| Tax provision | $21.42M | -$2.77M | $2.78M | $3.79M | +874.1% |
| Net income | -$1.63M | -$599.49M | -$205.28M | -$176.06M | +99.7% |
| Net income to common | -$1.63M | -$599.49M | -$205.28M | -$176.06M | +99.7% |
| Basic EPS | -0.01 | -5.00 | -1.91 | -1.63 | +99.8% |
| Diluted EPS | -0.01 | -5.00 | -1.92 | -1.67 | +99.8% |
| EBIT | $140.89M | -$580.11M | -$188.16M | -$172.71M | +124.3% |
| EBITDA | $164.82M | -$561.51M | -$175.67M | -$162.29M | +129.4% |
| Basic shares | 133.76M | 119.78M | 107.31M | 105.96M | +11.7% |
| Diluted shares | 133.76M | 119.78M | 107.31M | 105.96M | +11.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $88.71M | $76.21M | $110.89M | $108.00M | +16.4% |
| Cash & short-term investments | $919.37M | $680.96M | $403.63M | $376.40M | +35.0% |
| Accounts receivable | $6.82M | $0 | $0 | $1.41M | — |
| Total current assets | $950.64M | $695.47M | $416.47M | $405.30M | +36.7% |
| Property, plant & equipment | $426.41M | $431.29M | $335.56M | $168.59M | -1.1% |
| Goodwill & intangibles | $6.86M | $8.56M | $10.26M | $11.96M | -19.9% |
| Total assets | $1.39B | $1.14B | $765.55M | $691.94M | +21.5% |
| Total current liabilities | $195.49M | $103.17M | $105.46M | $138.85M | +89.5% |
| Current debt | $40.00M | — | — | — | — |
| Long-term debt | $214.88M | $393.18M | — | — | -45.3% |
| Total debt | $366.28M | $510.55M | $115.17M | $81.58M | -28.3% |
| Total liabilities | $881.88M | $948.74M | $478.39M | $273.60M | -7.0% |
| Retained earnings | -$1.63B | -$1.63B | -$1.03B | -$820.75M | -0.1% |
| Shareholder equity | $466.05M | $185.44M | $271.34M | $398.52M | +151.3% |
| Working capital | $755.15M | $592.30M | $311.02M | $266.45M | +27.5% |
| Net tangible assets | $459.19M | $176.88M | $261.08M | $386.56M | +159.6% |
| Shares issued | 138.36M | 124.38M | 107.31M | 105.96M | +11.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $30.11M | -$609.69M | -$209.28M | -$176.49M | +104.9% |
| Depreciation & amortisation | $23.93M | $18.59M | $12.49M | $10.42M | +28.7% |
| Stock-based compensation | $63.37M | $73.97M | $78.13M | $120.89M | -14.3% |
| Change in working capital | -$18.23M | $25.09M | -$51.55M | -$98.29M | -172.7% |
| Operating cash flow | $179.55M | -$462.85M | -$153.89M | -$136.13M | +138.8% |
| Capital expenditure | -$22.67M | -$141.47M | -$176.74M | -$52.78M | +84.0% |
| Investing cash flow | -$129.29M | -$420.07M | -$96.16M | -$5.42M | +69.2% |
| Financing cash flow | $74.01M | $870.52M | $253.05M | $65.19M | -91.5% |
| Free cash flow | $156.89M | -$604.32M | -$330.63M | -$188.91M | +126.0% |
| End cash position | $226.55M | $102.69M | $110.89M | $108.00M | +120.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $75.25M | $73.74M | $264.03M | $256.47M | $27.77M | — | +2.1% |
| Operating revenue | $75.25M | $73.74M | $264.03M | $256.47M | $27.77M | — | +2.1% |
| Research & development | $198.22M | $173.25M | $177.20M | $174.69M | $162.37M | — | +14.4% |
| Selling, general & admin | $46.63M | $41.24M | $45.52M | $37.18M | $30.44M | — | +13.1% |
| Total operating expense | $245.35M | $215.00M | $223.22M | $212.37M | $193.32M | — | +14.1% |
| Operating income | -$170.09M | -$141.26M | $40.81M | $44.11M | -$165.55M | — | -20.4% |
| Net interest income | -$7.63M | -$6.98M | -$12.81M | -$12.64M | -$13.36M | — | -9.3% |
| Pre-tax income | -$178.91M | -$137.56M | $28.27M | $36.12M | -$179.09M | — | -30.1% |
| Tax provision | $11.00K | $7.00K | $29.00K | $20.00M | -$437.00K | — | +57.1% |
| Net income | -$194.28M | -$132.73M | $30.81M | -$23.75M | -$175.24M | — | -46.4% |
| Net income to common | -$194.28M | -$132.73M | $30.81M | -$23.75M | -$175.24M | — | -46.4% |
| Basic EPS | -1.36 | -0.93 | 0.22 | — | -1.26 | 2.78 | -46.2% |
| Diluted EPS | -1.36 | -0.93 | 0.22 | — | -1.26 | 2.75 | -46.2% |
| EBIT | -$154.34M | -$113.72M | $50.78M | $57.81M | -$154.71M | — | -35.7% |
| EBITDA | -$147.68M | -$107.35M | $57.17M | $64.20M | -$148.48M | — | -37.6% |
| Basic shares | 143.38M | 142.42M | 137.04M | — | 139.04M | 133.36M | +0.7% |
| Diluted shares | 143.38M | 142.42M | 140.71M | — | 139.04M | 134.48M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.68M | $147.53M | $71.37M | $88.71M | $129.79M | -86.7% |
| Cash & short-term investments | $1.60B | $1.78B | $916.61M | $919.37M | $900.37M | -10.2% |
| Accounts receivable | $8.56M | $15.69M | $218.87M | $6.82M | $9.70M | -45.5% |
| Total current assets | $1.67B | $1.84B | $1.17B | $950.64M | $946.92M | -9.2% |
| Property, plant & equipment | $428.97M | $417.62M | $421.94M | $426.41M | $425.05M | +2.7% |
| Goodwill & intangibles | $5.59M | $6.01M | $6.44M | $6.86M | $7.29M | -7.1% |
| Total assets | $2.11B | $2.27B | $1.60B | $1.39B | $1.38B | -6.9% |
| Total current liabilities | $283.35M | $295.22M | $347.43M | $195.49M | $194.53M | -4.0% |
| Current debt | $40.00M | $40.00M | $40.00M | $40.00M | $40.00M | 0.0% |
| Long-term debt | $824.07M | $841.58M | $163.11M | $214.88M | $200.33M | -2.1% |
| Total debt | $983.69M | $989.46M | $312.77M | $366.28M | $353.03M | -0.6% |
| Total liabilities | $1.65B | $1.67B | $1.04B | $881.88M | $860.81M | -1.4% |
| Retained earnings | -$1.92B | -$1.73B | -$1.60B | -$1.63B | -$1.60B | -11.2% |
| Shareholder equity | $465.53M | $613.98M | $568.42M | $466.05M | $522.31M | -24.2% |
| Working capital | $1.39B | $1.54B | $826.96M | $755.15M | $752.39M | -10.1% |
| Net tangible assets | $459.94M | $607.97M | $561.99M | $459.19M | $515.03M | -24.3% |
| Shares issued | 141.13M | 143.23M | 140.05M | 138.36M | 138.14M | -1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$178.92M | -$137.57M | $28.24M | $16.12M | -$178.65M | -30.1% |
| Depreciation & amortisation | $6.66M | $6.37M | $6.39M | $6.39M | $6.22M | +4.6% |
| Stock-based compensation | $14.87M | $16.67M | $19.37M | $19.09M | $13.04M | -10.8% |
| Change in working capital | -$45.51M | $188.15M | -$61.79M | -$38.36M | -$17.96M | -124.2% |
| Operating cash flow | -$177.47M | $84.44M | $13.48M | $20.49M | -$154.72M | -310.2% |
| Capital expenditure | -$3.85M | -$2.56M | -$2.15M | -$7.49M | -$2.36M | -50.3% |
| Investing cash flow | $43.68M | -$894.28M | -$23.74M | $72.62M | $141.39M | +104.9% |
| Financing cash flow | -$449.00K | $795.72M | -$14.75M | $3.67M | -$42.68M | -100.1% |
| Free cash flow | -$181.32M | $81.88M | $11.33M | $13.00M | -$157.08M | -321.5% |
| End cash position | $54.76M | $188.52M | $201.64M | $226.55M | $129.79M | -71.0% |
Options analytics
Put / call volume
0.25
Call-heavy session
Put / call open interest
0.28
Positioning, not flow
Max pain
67.50
+9.7% from spot
ATM implied vol
58.0%
Nearest strike to spot
Skew (10% OTM)
-46.3%
Calls bid over puts
Call volume
1.73K
Contracts, this expiry
Put volume
431
Contracts, this expiry
Heaviest call OI
85.00
1.13K contracts
Heaviest put OI
75.00
1.00K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.23 | -1.36 | -10.4% |
| Mar 2026 | -1.11 | -0.93 | +16.0% |
| Dec 2025 | -0.37 | 0.22 | +159.9% |
| Sep 2025 | -0.16 | -0.18 | -14.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.54 | 14 | $58.53M | -77.2% |
| Next quarter | -1.37 | 7 | $45.76M | -82.7% |
| Current year | -3.54 | 14 | $461.74M | -44.3% |
| Next year | -4.93 | 14 | $334.32M | -27.6% |
Analyst targets & ownership
Mean target$107.23
High target$126.00
Low target$74.00
Implied upside74.25%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy4 / 9
Hold1
Sell / Strong sell0 / 0
Held by insiders3.66%
Held by institutions85.38%
Institutions holding656
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
64.36
-4.38% from price
SMA 20
68.41
-10.04% from price
SMA 50
79.39
-22.48% from price
SMA 100
78.74
-21.84% from price
SMA 200
72.43
-15.04% from price
EMA 12
65.38
-5.88% from price
EMA 26
70.45
-12.65% from price
EMA 50
74.72
-17.64% from price
RSI (14)
26.8
Oversold
MACD (12,26,9)
-5.07
Hist -0.22
ATR (14)
2.52
4.09% of price
Realised vol 30D
54.1%
Annualised
Bollinger upper
80.98
20, 2σ
Bollinger lower
55.83
20, 2σ
50 / 200 cross
Golden
79.39 vs 72.43
Trend bias
Below 200
-15.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.57
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
54.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.3%
Peak to trough
Max drawdown 5Y
-87.9%
Peak to trough
ATR 14
2.52
4.09% of price
Beta (reported)
1.30
5Y monthly, from filing
Short interest
Shares short
9.27M
Prior 9.21M
Change vs prior
+0.7%
Shorts adding
% of float
9.13%
Normal
% of shares out
6.56%
Against total outstanding
Days to cover
6.4
Crowded exit
Float
122.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | Citigroup | INITIATED | — | Buy |
| Sep 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 31, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 31, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 30, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Jul 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 23, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 23, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 22, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jul 17, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 14, 26 | Stifel | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateNov 17, 2011
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-03-20
Corporate Changes & Voting Matters
8-K · 2026-02-05
Proxy Statements
DEF 14A · 2026-01-27
Corporate Changes & Voting Matters
8-K · 2026-01-12
Corporate Changes & Voting Matters
8-K · 2026-01-09
Headlines
Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday
MT Newswires · 30m ago
Arrowhead Says US FDA Includes Plozasiran in Split Real Time Application Review Pilot Program
MT Newswires · 2h ago
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Business Wire · 2h ago
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Business Wire · 8d ago
RNAi drug specialist ADARx raises $446M IPO
BioPharma Dive · 13d ago
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Stocktwits · 13d ago
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
Simply Wall St. · 18d ago
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
MarketBeat · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.